125 related articles for article (PubMed ID: 21106451)
1. Novel TNF-α converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.
Girijavallabhan VM; Chen L; Dai C; Feltz RJ; Firmansjah L; Li D; Kim SH; Kozlowski JA; Lavey BJ; Kosinski A; Piwinski JJ; Popovici-Muller J; Rizvi R; Rosner KE; Shankar BB; Shih NY; Siddiqui MA; Tong L; Wong MK; Yang DY; Yang L; Yu W; Zhou G; Guo Z; Orth P; Madison V; Bian H; Lundell D; Niu X; Shah H; Sun J; Umland S
Bioorg Med Chem Lett; 2010 Dec; 20(24):7283-7. PubMed ID: 21106451
[TBL] [Abstract][Full Text] [Related]
2. Fused bi-heteroaryl substituted hydantoin compounds as TACE inhibitors.
Tong L; Kim SH; Rosner K; Yu W; Shankar BB; Chen L; Li D; Dai C; Girijavallabhan V; Popovici-Muller J; Yang L; Zhou G; Kosinski A; Siddiqui MA; Shih NY; Guo Z; Orth P; Chen S; Lundell D; Niu X; Umland S; Kozlowski JA
Bioorg Med Chem Lett; 2017 Jul; 27(14):3037-3042. PubMed ID: 28558971
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.
Gilmore JL; King BW; Harris C; Maduskuie T; Mercer SE; Liu RQ; Covington MB; Qian M; Ribadeneria MD; Vaddi K; Trzaskos JM; Newton RC; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2006 May; 16(10):2699-704. PubMed ID: 16516466
[TBL] [Abstract][Full Text] [Related]
4. The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.
Rosner KE; Guo Z; Orth P; Shipps GW; Belanger DB; Chan TY; Curran PJ; Dai C; Deng Y; Girijavallabhan VM; Hong L; Lavey BJ; Lee JF; Li D; Liu Z; Popovici-Muller J; Ting PC; Vaccaro H; Wang L; Wang T; Yu W; Zhou G; Niu X; Sun J; Kozlowski JA; Lundell DJ; Madison V; McKittrick B; Piwinski JJ; Shih NY; Arshad Siddiqui M; Strickland CO
Bioorg Med Chem Lett; 2010 Feb; 20(3):1189-93. PubMed ID: 20022498
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humans.
Qian M; Bai SA; Brogdon B; Wu JT; Liu RQ; Covington MB; Vaddi K; Newton RC; Fossler MJ; Garner CE; Deng Y; Maduskuie T; Trzaskos J; Duan JJ; Decicco CP; Christ DD
Drug Metab Dispos; 2007 Oct; 35(10):1916-25. PubMed ID: 17656469
[TBL] [Abstract][Full Text] [Related]
6. Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme.
Zhang Y; Hegen M; Xu J; Keith JC; Jin G; Du X; Cummons T; Sheppard BJ; Sun L; Zhu Y; Rao VR; Wang Q; Xu W; Cowling R; Nickerson-Nutter CL; Gibbons J; Skotnicki J; Lin LL; Levin J
Int Immunopharmacol; 2004 Dec; 4(14):1845-57. PubMed ID: 15531300
[TBL] [Abstract][Full Text] [Related]
7. Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Duan JJ; Chen L; Lu Z; Jiang B; Asakawa N; Sheppeck JE; Liu RQ; Covington MB; Pitts W; Kim SH; Decicco CP
Bioorg Med Chem Lett; 2007 Jan; 17(1):266-71. PubMed ID: 17027261
[TBL] [Abstract][Full Text] [Related]
8. Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors.
Duan JJ; Chen L; Lu Z; Xue CB; Liu RQ; Covington MB; Qian M; Wasserman ZR; Vaddi K; Christ DD; Trzaskos JM; Newton RC; Decicco CP
Bioorg Med Chem Lett; 2008 Jan; 18(1):241-6. PubMed ID: 18032037
[TBL] [Abstract][Full Text] [Related]
9. Structure and activity relationships of tartrate-based TACE inhibitors.
Li D; Popovici-Muller J; Belanger DB; Caldwell J; Dai C; David M; Girijavallabhan VM; Lavey BJ; Lee JF; Liu Z; Mazzola R; Rizvi R; Rosner KE; Shankar B; Spitler J; Ting PC; Vaccaro H; Yu W; Zhou G; Zhu Z; Niu X; Sun J; Guo Z; Orth P; Chen S; Kozlowski JA; Lundell DJ; Madison V; McKittrick B; Piwinski JJ; Shih NY; Shipps GW; Siddiqui MA; Strickland CO
Bioorg Med Chem Lett; 2010 Aug; 20(16):4812-5. PubMed ID: 20638281
[TBL] [Abstract][Full Text] [Related]
10. Design strategies for the identification of MMP-13 and Tace inhibitors.
Skotnicki JS; DiGrandi MJ; Levin JI
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.
Mazzola RD; Zhu Z; Sinning L; McKittrick B; Lavey B; Spitler J; Kozlowski J; Neng-Yang S; Zhou G; Guo Z; Orth P; Madison V; Sun J; Lundell D; Niu X
Bioorg Med Chem Lett; 2008 Nov; 18(21):5809-14. PubMed ID: 18835710
[TBL] [Abstract][Full Text] [Related]
12. Biaryl substituted hydantoin compounds as TACE inhibitors.
Yu W; Tong L; Kim SH; Wong MK; Chen L; Yang DY; Shankar BB; Lavey BJ; Zhou G; Kosinski A; Rizvi R; Li D; Feltz RJ; Piwinski JJ; Rosner KE; Shih NY; Siddiqui MA; Guo Z; Orth P; Shah H; Sun J; Umland S; Lundell DJ; Niu X; Kozlowski JA
Bioorg Med Chem Lett; 2010 Sep; 20(17):5286-9. PubMed ID: 20663669
[TBL] [Abstract][Full Text] [Related]
13. Current perspective of TACE inhibitors: a review.
DasGupta S; Murumkar PR; Giridhar R; Yadav MR
Bioorg Med Chem; 2009 Jan; 17(2):444-59. PubMed ID: 19095454
[TBL] [Abstract][Full Text] [Related]
14. Discovery of selective small molecular TACE inhibitors for the treatment of rheumatoid arthritis.
Li NG; Shi ZH; Tang YP; Wei-Li ; Lian-Yin ; Duan JA
Curr Med Chem; 2012; 19(18):2924-56. PubMed ID: 22519396
[TBL] [Abstract][Full Text] [Related]
15. Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Ott GR; Asakawa N; Liu RQ; Covington MB; Qian M; Vaddi K; Newton RC; Trzaskos JM; Christ DD; Galya L; Scholz T; Marshall W; Duan JJ
Bioorg Med Chem Lett; 2008 Feb; 18(4):1288-92. PubMed ID: 18234496
[TBL] [Abstract][Full Text] [Related]
16. Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.
Levin JI; Chen JM; Laakso LM; Du M; Schmid J; Xu W; Cummons T; Xu J; Jin G; Barone D; Skotnicki JS
Bioorg Med Chem Lett; 2006 Mar; 16(6):1605-9. PubMed ID: 16426848
[TBL] [Abstract][Full Text] [Related]
17. Development of a prodrug of hydantoin based TACE inhibitor.
Tong L; Kim SH; Chen L; Kosinski A; Shankar BB; Girijavallabhan V; Yang DY; Yu W; Zhou G; Shih NY; Chen S; Hu M; Lundell D; Niu X; Umland S; Kozlowski JA
Bioorg Med Chem Lett; 2017 Aug; 27(16):3704-3708. PubMed ID: 28711352
[TBL] [Abstract][Full Text] [Related]
18. Novel TACE inhibitors in drug discovery: a review of patented compounds.
Murumkar PR; DasGupta S; Chandani SR; Giridhar R; Yadav MR
Expert Opin Ther Pat; 2010 Jan; 20(1):31-57. PubMed ID: 20021284
[TBL] [Abstract][Full Text] [Related]
19. Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents.
Lu Z; Ott GR; Anand R; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Trzaskos J; Duan JJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1958-62. PubMed ID: 18282708
[TBL] [Abstract][Full Text] [Related]
20. Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).
Ott GR; Asakawa N; Lu Z; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Traskos JM; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2008 Jan; 18(2):694-9. PubMed ID: 18061445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
